ILiAD Biotechnologies closed an oversubscribed $115 million Series B to advance its BPZE1 pertussis vaccine.
- Amount
- $115M
- Stage
- Series B
- Announced
- 10 February 2026
- Lead
- RA Capital Management
- Other investors
- Janus Henderson Investors, BNP Paribas Asset Management Alts, AI Life Sciences
- Use of funds
- Advancing next-generation pertussis vaccine BPZE1 through Phase 3 development and pivotal study starting 2026.
- Total raised
- $215M to date
- Checked
- Amount and date checked against the press source